Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Lisata Therapeutics (LSTA) over the last 11 years, with Q3 2025 value amounting to -$4.2 million.

  • Lisata Therapeutics' Income towards Parent Company rose 1381.34% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.2 million, marking a year-over-year increase of 1204.44%. This contributed to the annual value of -$20.0 million for FY2024, which is 410.27% up from last year.
  • According to the latest figures from Q3 2025, Lisata Therapeutics' Income towards Parent Company is -$4.2 million, which was up 1381.34% from -$4.7 million recorded in Q2 2025.
  • Lisata Therapeutics' 5-year Income towards Parent Company high stood at -$4.0 million for Q2 2023, and its period low was -$6.2 million during Q1 2023.
  • Over the past 3 years, Lisata Therapeutics' median Income towards Parent Company value was -$4.9 million (recorded in 2024), while the average stood at -$5.0 million.
  • Within the past 5 years, the most significant YoY rise in Lisata Therapeutics' Income towards Parent Company was 1407.27% (2024), while the steepest drop was 2525.45% (2024).
  • Lisata Therapeutics' Income towards Parent Company (Quarter) stood at -$5.4 million in 2023, then increased by 14.07% to -$4.6 million in 2024, then grew by 7.83% to -$4.2 million in 2025.
  • Its Income towards Parent Company stands at -$4.2 million for Q3 2025, versus -$4.7 million for Q2 2025 and -$4.7 million for Q1 2025.